EDN1 and atherosclerosis: Since bothincreased ET-1 production and decreased NO bioavailability are deeply involvedin the pathophysiology of atherosclerosis [22], reciprocal changes in ET-1 andNO production by the vascular endothelium could contribute to the benefitsderiving from clinical use of ACE inhibitors [2].